Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trialPaul M. Ridker, Hakan Kültürsay, Peter Siostrzonek et al.|The Lancet|2017Cited by 1.3k
Visualization of coronary atherosclerotic plaques in patients using optical coherence tomography: comparison with intravascular ultrasoundIk‐Kyung Jang, Guillermo J. Tearney, Brett E. Bouma et al.|Journal of the American College of Cardiology|2002Cited by 1k
Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trialPaul M. Ridker, Patrick Commerford, Jean MacFadyen et al.|The Lancet|2017Cited by 881
Optimal Duration of Dual Antiplatelet Therapy After Drug-Eluting Stent ImplantationCheol Whan Lee, Seung‐Jung Park, Jung‐Min Ahn et al.|Circulation|2013Cited by 281